# Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

> **NCT02349386** · PHASE2 · TERMINATED · sponsor: **BHR Pharma, LLC** · enrollment: 34 (actual)

## Conditions studied

- Cancer of the Prostate

## Interventions

- **DRUG:** BHR-200 (0.36% transdermal 17β-estradiol gel)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02349386
- **Lead sponsor:** BHR Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2017-06-14
- **Final completion:** 2018-01-10
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Inability to recruit patients
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349386, "Maintaining Suppression of Testosterone With Transdermal Estradiol Gel". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02349386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*